Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome
Recruiting · Phase 2 · NCT05873712
Conditions: Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma, Recurrent Transformed B-Cell Non-Hodgkin Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma, Refractory Transformed B-cell Non-Hodgkin Lymphoma, Refractory Transformed
At a glance
- Research payments reported, 2025
- $82,297
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 24
About the trial
- Sponsor
- Aseel Alsouqi (with BeOne Medicines)
- Tested
- Biospecimen Collection (procedure), Bone Marrow Biopsy (procedure), Computed Tomography (procedure), Cyclophosphamide (drug), Fludarabine (drug), Leukapheresis (procedure), Lisocabtagene Maraleucel (biological), Lymph Node Biopsy (procedure), Positron Emission Tomography (procedure), Zanubrutinib (drug)
- Dates
- Started 2023-07-28; completion 2026-12-31
- Results posted
- Not yet
This phase II trial tests how well zanubrutinib and lisocabtagene maraleucel (liso-cel) work together in treating patients with Richter's syndrome that has come back (recurrent) or does not respond to treatment (refractory). Richter's syndrome occurs when chronic lymphocytic leukemia and/or small lymphocytic leukemia transforms into an aggressive lymphoma, which is a cancer of the lymph nodes. Zanubrutinib is a class of medication called a kinase inhibitor. These drugs work by preventing the action of abnormal proteins that tell cancer cells to multiply, which helps stop the spread of cancer. Liso-cel is a type of treatment known as chimeric antigen receptor (CAR) T cell therapy. CAR T-ce…
From ClinicalTrials.gov, last updated 2026-03-03. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beigene USA, Inc. reported $82,297 in research payments for this study in 2025 (1 payments).
Products named: Brukinsa
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- The Ohio State University Dba: Comprehensive Canc $82,297
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.